Leonardo da Fonseca achieved his medical degree at Faculdade de Medicina da Universidade de Sao Paulo (FMUSP) in 2008. He obtained Internal Medicine certification at Hospital das Clínicas da FMUSP (2010–2012) and concluded the fellowship program in Medical Oncology at Instituto do Cancer do Estado de Sao Paulo (ICESP-FMUSP, 2012-2017) where he is part of the gastrointestinal cancer group. In 2018, he earned a Master degree in Clinical Research (with specialisation in liver diseases) from University of Barcelona and is currently a pre doctoral fellow in the Barcelona Clinic Liver Cancer group. Relevant Publications: Díaz-González, Á; Sanduzzi-Zamparelli, M; Sapena, V; Torres, F; Llarch, N; Iserte, G; Forner, A; Da Fonseca, LG ; Ríos, J; Bruix, J; Reig, M. Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2019;49(5):482-491. Reig, M; Da Fonseca LG ; Faivre, S. New trials and results in systemic treatment of HCC. J Hepatol 2018;69(2):525-533. 
Da Fonseca LG, Reig M, Bruix J. Systemic therapy for hepatocellular carcinoma: trial enrichment does not guarantee success. Oncotarget 2018;9(73):33741-33742. Da Fonseca LG, Forner A. Carbon-ion radiotherapy for HCC-A potential tool to fulfil an unmet gap in the treatment algorithms? Liver Int 2018;38(12):2132-2133. Da Fonseca LG, Marta GN, Braghiroli MIFM, Chagas AL, Carrilho FJ, Hoff PM, Sabbaga J. Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib. BMC Cancer 2018;18(1):1250. Silva ACB, Vicentini MFB, Mendoza EZ, Fujiki FK, da Fonseca LG, Braghiroli MIFM, Hoff PM. Young-age onset colorectal cancer in Brazil: Analysis of incidence, clinical features, and outcomes in a tertiary cancer center. Curr Probl Cancer 2019 [Epub ahead of print] 
Landeiro LCG, Gagliato DM, Fêde AB, Fraile NM, Lopez RM, da Fonseca LG, Petry V, Testa L, Hoff PM, Mano MS. Return to work after breast cancer diagnosis: An observational prospective study in Brazil. Cancer 2018;124(24):4700-4710. Da Fonseca LG, Barroso-Sousa R, Bento AD, Blanco BP, Valente GL, Pfiffer TE, Hoff PM, Sabbaga J. Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma. Mol Clin Oncol 2015;3(4):793-796. 
Da Fonseca LG, Barroso-Sousa R, Bento Ada S, Blanco BP, Valente GL, Pfiffer TE, Hoff PM, Sabbaga J. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Med Oncol 2014;31(11):264. Ramos REO, Perez Mak M, Alves MFS, Piotto GHM, Takahashi TK, da Fonseca LG, Silvino MCM, Hoff PM, de Castro G Jr. Malignancy-Related Hypercalcemia in Advanced Solid Tumors: Survival Outcomes. J Glob Oncol 2017;3(6):728-733. Mota JM, da Fonseca LG, Braghiroli MI, Hoff PM. Review on TAS-102 development and its use for metastatic colorectal cancer. Crit Rev Oncol Hematol 2016;104:91-7. Barroso-Sousa R, da Fonseca LG, Souza KT, Chaves AC, Kann AG, de Castro G Jr, Dzik C. Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Med Oncol 2015;32(1):443. 
Da Fonseca LG, Marques DF, Takahashi TK, Aguiar FN, Ravanini JN, Saragiotto DF. Malignant paratesticular mesothelioma. Autops Case Rep 2014;4(1):45-51. Da Fonseca LG, de Melo Gagliato D, Takahashi TK, Mak MP, Barroso-Sousa R, Testa L, Helena VP, de Paula Costa R, Hoff PM, Mano MS. Cardiac safety of (neo)adjuvant trastuzumab in the community setting: a single-center experience. Breast Care (Basel) 2014;9(4):255-60. Abreu AP, Milani C, Katayama ML, Barbosa KC, Da Fonseca LG, Goes JC,Brentani MM, Koike Folgueira MA. Expression of heterochromatin protein 1 in the primary tumor of breast cancer patients in the presence or absence of occult metastatic cells in the bone marrow. Int J Biol Markers 2008;23(4):219-24.